Even though EGFR-targeted cancer therapy is initially effective against KRAS-wild-type cancers, drug resistance is prevalent in patients receiving several cycles of treatment, highlighting the urgent need to design novel therapeutic modalities. The gene discussed is EGFR; the disease is cancer.